This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Neurodegenerative Disease Market

Market Insights on Neurodegenerative Disease covering sales outlook, demand forecast & up-to-date key trends

Neurodegenerative Disease Market by Drug Class, Disease Indication & Region - Forecast 2022 – 2032

Neurodegenerative Disease Market Overview (2022-2032)

[250 Pages Report] The neurodegenerative disease market is anticipated to register a CAGR of 7% during the forecast period, up from US$ 43.7 Bn in 2021 to reach a valuation of US$ 92 Bn by 2032.

The neurodegenerative disease market is anticipated to show promising growth prospects during the forecasted period due to the increasing frequency of neurological diseases, an aging population, and growing demand for Alzheimer's and Parkinson's disease treatments.

Attributes

Details

Neurodegenerative Disease Market Value (2021)

US$ 43.7 Bn

Neurodegenerative Disease Market Value (2032)

US$ 92 Bn

CAGR (2021-2032)

7%

The neurodegenerative disease market share is expected to grow significantly, mainly due to increasing cases of neurodegenerative disorders. The neurodegenerative disease market is expected to witness advancement in the upcoming years due to a new type of drug launch.

Due to patent protection loss, new players are expected to enter the neurodegenerative disease market during the forecast years. In the Alzheimer’s market, drugs like GABA receptor modulators, anti-amyloid protein agents and nicotinic and cholinergic receptor agonists are expected to influence the neurodegenerative disease market growth.

However, the Parkinson’s disease market will be driven due to the launch of drugs like dopamine receptor agonists and reuptake inhibitors, glutamate receptor modulators, and adrenergic and adenosine antagonists.

Customize this Report

Let us know your requirement to get
100% FREE customization

What are the Key Drivers to the Neurodegenerative Disease Market Share?

The neurodegenerative disease market is expected to thrive as medical technology advances for the detection and rising demand for the treatment of neurodegenerative diseases, increasing the need for neurodegenerative drugs.

The aging population is leading to an increase in the frequency of neurodegenerative diseases, which is one of the primary reasons driving the growth of the neurodegenerative market.

Developing nations, particularly those in the Asia Pacific, are predicted to be strong in the future years.

Growing physician awareness is assisting the neurodegenerative disease market growth to remain in developed countries. Due to the illness's multifaceted character, the lack of comprehensive curative treatment measures might hinder the global neurodegenerative disease market.

The neurodegenerative disease continues to place a significant strain on global healthcare costs and population mental and physical health. All disorders that impact the neurons in the human brain are classified as neurodegenerative diseases.

Alzheimer's disease is the most common neurodegenerative illness, with an estimated 5.8 million instances of Alzheimer's dementia in the United States alone in 2019. Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, spinal muscular atrophy, multiple system atrophy, and others are examples of neurodegenerative diseases.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Which is the Leading Region in the Neurodegenerative Disease Market?

North America generated US$ 18,174.6 Mn in revenue from sales of neurodegenerative diseases drugs in 2018 and is likely to lead the neurodegenerative diseases market during the forecast period.

Growing medication demand, high prices, increased R&D investment, and favorable health reimbursement policies are driving the growth of the neurodegenerative diseases market in North America.

The European neurodegenerative disease market is expected to increase significantly due to the active government backing and marketing clearance for SPINRAZA in June 2017.

The Asia Pacific neurodegenerative diseases drugs market sales are expected to grow at the fastest rate during the forecast period, owing to the rising prevalence of neurodegenerative diseases, an aging population, and increased demand for Alzheimer's and Parkinson's disease drugs in Japan and China.

Some of the key market players in the global neurodegenerative disease market are Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA Pharmaceuticals Industries, UCB, Boehringer Ingelheim, Sanofi S.A., GlaxoSmithKline. Due to patent protection loss, significant players in the neurodegenerative disease market will face competition in the upcoming years.

Recent Developments

  • Luye Pharma and Towa Pharmaceutical announced a strategic agreement in February 2021 to develop and market Rivastigmine Multi-Day Transdermal Patch in Japan. Luye Pharma created the Rivastigmine Multi-Day Transdermal Patch, which treats Alzheimer's disease.
  • Eli Lilly and Business finalized the purchase of Prevail, a biotechnology company exploring potentially disease-modifying AAV9-based gene treatments for patients suffering from neurodegenerative diseases, in January 2021.
Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Scope of Report

Report Attribute

Details

Growth rate

CAGR of 7% from 2022 to 2032

Base year for estimation

2021

Historical data

2015 - 2020

Forecast period

2022 - 2032

Quantitative units

Revenue in USD million, volume in kilotons, and CAGR from 2022 to 2032

Report coverage

Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis,

Segments covered

Drug class, disease indication, region

Regional scope

North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia and New Zealand

Country scope

U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa

Key companies profiled

Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA Pharmaceuticals Industries, UCB, Boehringer Ingelheim, Sanofi S.A., GlaxoSmithKline

Customization scope

Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs.

Frequently Asked Questions

The neurodegenerative disease market is likely to register a CAGR of 7% during the forecast period.

Key players holding substantial neurodegenerative disease market share include Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA Pharmaceuticals Industries, UCB, Boehringer Ingelheim, Sanofi S.A., GlaxoSmithKline

As per the analysis, the neurodegenerative disease market share is likely to be US$ 92 Bn by 2032.

Demand for neurodegenerative disease treatment is likely to rise due to increasing prevalence of neurological diseases, an ageing population, and an increase in demand for Alzheimer's and Parkinson's disease treatments.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Neurodegenerative Disease Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Neurodegenerative Disease Market Analysis 2017-2021 and Forecast 2022-2032, By Disease Indication

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Disease Indication, 2017-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease Indication, 2022-2032

        5.3.1. Alzheimer’s Disease

        5.3.2. Motor Neuron Diseases

        5.3.3. Parkinson’s Disease

        5.3.4. Huntington’s Disease

        5.3.5. Multiple Sclerosis

        5.3.6. Others

    5.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2017-2021

    5.5. Absolute $ Opportunity Analysis By Disease Indication, 2022-2032

Deep-dive segmentation will be available in the sample on request

6. Global Neurodegenerative Disease Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2017-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2022-2032

        6.3.1. Cholinesterase Inhibitors

        6.3.2. Dopamine Inhibitors

        6.3.3. MAO-B Inhibitors

        6.3.4. Catechol-O-methyltransferase Inhibitors

        6.3.5. Anticholinergics

        6.3.6. Antipsychotic Drugs

        6.3.7. Dopamine Antagonists

        6.3.8. Others

    6.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017-2021

    6.5. Absolute $ Opportunity Analysis By Drug Class, 2022-2032

Deep-dive segmentation will be available in the sample on request

7. Global Neurodegenerative Disease Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2017-2021

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2032

        7.3.1. Oral Drugs

        7.3.2. Parenteral Drugs

        7.3.3. Topical Drugs

    7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017-2021

    7.5. Absolute $ Opportunity Analysis By Route of Administration, 2022-2032

Deep-dive segmentation will be available in the sample on request

8. Global Neurodegenerative Disease Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021

    8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

        8.3.4. Drug Stores

    8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021

    8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032

Deep-dive segmentation will be available in the sample on request

9. Global Neurodegenerative Disease Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

    9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. East Asia

        9.3.5. South Asia & Pacific

        9.3.6. MEA

    9.4. Market Attractiveness Analysis By Region

10. North America Neurodegenerative Disease Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. U.K.

            10.2.1.2. Canada

        10.2.2. By Disease Indication

        10.2.3. By Drug Class

        10.2.4. By Route of Administration

        10.2.5. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Disease Indication

        10.3.3. By Drug Class

        10.3.4. By Route of Administration

        10.3.5. By Distribution Channel

    10.4. Key Takeaways

11. Latin America Neurodegenerative Disease Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Disease Indication

        11.2.3. By Drug Class

        11.2.4. By Route of Administration

        11.2.5. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Disease Indication

        11.3.3. By Drug Class

        11.3.4. By Route of Administration

        11.3.5. By Distribution Channel

    11.4. Key Takeaways

12. Europe Neurodegenerative Disease Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. U.K.

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Europe

        12.2.2. By Disease Indication

        12.2.3. By Drug Class

        12.2.4. By Route of Administration

        12.2.5. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Disease Indication

        12.3.3. By Drug Class

        12.3.4. By Route of Administration

        12.3.5. By Distribution Channel

    12.4. Key Takeaways

13. East Asia Neurodegenerative Disease Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Disease Indication

        13.2.3. By Drug Class

        13.2.4. By Route of Administration

        13.2.5. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Disease Indication

        13.3.3. By Drug Class

        13.3.4. By Route of Administration

        13.3.5. By Distribution Channel

    13.4. Key Takeaways

14. South Asia & Pacific Neurodegenerative Disease Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        14.2.1. By Country

            14.2.1.1. India

            14.2.1.2. Thailand

            14.2.1.3. Indonesia

            14.2.1.4. Malaysia

            14.2.1.5. Singapore

            14.2.1.6. Australia

            14.2.1.7. New Zealand

            14.2.1.8. Rest of South Asia & Pacific

        14.2.2. By Disease Indication

        14.2.3. By Drug Class

        14.2.4. By Route of Administration

        14.2.5. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Disease Indication

        14.3.3. By Drug Class

        14.3.4. By Route of Administration

        14.3.5. By Distribution Channel

    14.4. Key Takeaways

15. MEA Neurodegenerative Disease Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    15.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    15.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Disease Indication

        15.2.3. By Drug Class

        15.2.4. By Route of Administration

        15.2.5. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Disease Indication

        15.3.3. By Drug Class

        15.3.4. By Route of Administration

        15.3.5. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Neurodegenerative Disease Market Analysis

    16.1. U.K.

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2021

            16.1.2.1. By Disease Indication

            16.1.2.2. By Drug Class

            16.1.2.3. By Route of Administration

            16.1.2.4. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2021

            16.2.2.1. By Disease Indication

            16.2.2.2. By Drug Class

            16.2.2.3. By Route of Administration

            16.2.2.4. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2021

            16.3.2.1. By Disease Indication

            16.3.2.2. By Drug Class

            16.3.2.3. By Route of Administration

            16.3.2.4. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2021

            16.4.2.1. By Disease Indication

            16.4.2.2. By Drug Class

            16.4.2.3. By Route of Administration

            16.4.2.4. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2021

            16.5.2.1. By Disease Indication

            16.5.2.2. By Drug Class

            16.5.2.3. By Route of Administration

            16.5.2.4. By Distribution Channel

    16.6. U.K.

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2021

            16.6.2.1. By Disease Indication

            16.6.2.2. By Drug Class

            16.6.2.3. By Route of Administration

            16.6.2.4. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2021

            16.7.2.1. By Disease Indication

            16.7.2.2. By Drug Class

            16.7.2.3. By Route of Administration

            16.7.2.4. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2021

            16.8.2.1. By Disease Indication

            16.8.2.2. By Drug Class

            16.8.2.3. By Route of Administration

            16.8.2.4. By Distribution Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2021

            16.9.2.1. By Disease Indication

            16.9.2.2. By Drug Class

            16.9.2.3. By Route of Administration

            16.9.2.4. By Distribution Channel

    16.10. China

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2021

            16.10.2.1. By Disease Indication

            16.10.2.2. By Drug Class

            16.10.2.3. By Route of Administration

            16.10.2.4. By Distribution Channel

    16.11. Japan

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2021

            16.11.2.1. By Disease Indication

            16.11.2.2. By Drug Class

            16.11.2.3. By Route of Administration

            16.11.2.4. By Distribution Channel

    16.12. South Korea

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2021

            16.12.2.1. By Disease Indication

            16.12.2.2. By Drug Class

            16.12.2.3. By Route of Administration

            16.12.2.4. By Distribution Channel

    16.13. India

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2021

            16.13.2.1. By Disease Indication

            16.13.2.2. By Drug Class

            16.13.2.3. By Route of Administration

            16.13.2.4. By Distribution Channel

    16.14. Thailand

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2021

            16.14.2.1. By Disease Indication

            16.14.2.2. By Drug Class

            16.14.2.3. By Route of Administration

            16.14.2.4. By Distribution Channel

    16.15. Indonesia

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2021

            16.15.2.1. By Disease Indication

            16.15.2.2. By Drug Class

            16.15.2.3. By Route of Administration

            16.15.2.4. By Distribution Channel

    16.16. Malaysia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2021

            16.16.2.1. By Disease Indication

            16.16.2.2. By Drug Class

            16.16.2.3. By Route of Administration

            16.16.2.4. By Distribution Channel

    16.17. Singapore

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2021

            16.17.2.1. By Disease Indication

            16.17.2.2. By Drug Class

            16.17.2.3. By Route of Administration

            16.17.2.4. By Distribution Channel

    16.18. Australia

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2021

            16.18.2.1. By Disease Indication

            16.18.2.2. By Drug Class

            16.18.2.3. By Route of Administration

            16.18.2.4. By Distribution Channel

    16.19. New Zealand

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2021

            16.19.2.1. By Disease Indication

            16.19.2.2. By Drug Class

            16.19.2.3. By Route of Administration

            16.19.2.4. By Distribution Channel

    16.20. GCC Countries

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2021

            16.20.2.1. By Disease Indication

            16.20.2.2. By Drug Class

            16.20.2.3. By Route of Administration

            16.20.2.4. By Distribution Channel

    16.21. South Africa

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2021

            16.21.2.1. By Disease Indication

            16.21.2.2. By Drug Class

            16.21.2.3. By Route of Administration

            16.21.2.4. By Distribution Channel

    16.22. Israel

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2021

            16.22.2.1. By Disease Indication

            16.22.2.2. By Drug Class

            16.22.2.3. By Route of Administration

            16.22.2.4. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Disease Indication

        17.3.3. By Drug Class

        17.3.4. By Route of Administration

        17.3.5. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. F. Hoffmann-La Roche Ltd

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Novartis AG

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Biogen

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Teva Pharmaceuticals Industries Ltd.

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Eisai Co., Ltd.

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Sanofi

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Merck KGaA

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. UCB S.A

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Boehringer Ingelheim International GmbH

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. GlaxoSmithKline plc

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

        18.1.11. Neuro-Hitech, Inc.

            18.1.11.1. Overview

            18.1.11.2. Product Portfolio

            18.1.11.3. Profitability by Market Segments

            18.1.11.4. Sales Footprint

            18.1.11.5. Strategy Overview

                18.1.11.5.1. Marketing Strategy

        18.1.12. BioVision Inc

            18.1.12.1. Overview

            18.1.12.2. Product Portfolio

            18.1.12.3. Profitability by Market Segments

            18.1.12.4. Sales Footprint

            18.1.12.5. Strategy Overview

                18.1.12.5.1. Marketing Strategy

        18.1.13. Aquinnah Pharmaceuticals

            18.1.13.1. Overview

            18.1.13.2. Product Portfolio

            18.1.13.3. Profitability by Market Segments

            18.1.13.4. Sales Footprint

            18.1.13.5. Strategy Overview

                18.1.13.5.1. Marketing Strategy

        18.1.14. ADDEX THERAPEUTICS

            18.1.14.1. Overview

            18.1.14.2. Product Portfolio

            18.1.14.3. Profitability by Market Segments

            18.1.14.4. Sales Footprint

            18.1.14.5. Strategy Overview

                18.1.14.5.1. Marketing Strategy

        18.1.15. Cellcentric

            18.1.15.1. Overview

            18.1.15.2. Product Portfolio

            18.1.15.3. Profitability by Market Segments

            18.1.15.4. Sales Footprint

            18.1.15.5. Strategy Overview

                18.1.15.5.1. Marketing Strategy

        18.1.16. Mission Therapeutics

            18.1.16.1. Overview

            18.1.16.2. Product Portfolio

            18.1.16.3. Profitability by Market Segments

            18.1.16.4. Sales Footprint

            18.1.16.5. Strategy Overview

                18.1.16.5.1. Marketing Strategy

        18.1.17. CogRx

            18.1.17.1. Overview

            18.1.17.2. Product Portfolio

            18.1.17.3. Profitability by Market Segments

            18.1.17.4. Sales Footprint

            18.1.17.5. Strategy Overview

                18.1.17.5.1. Marketing Strategy

        18.1.18. Denali Therapeutics Inc

            18.1.18.1. Overview

            18.1.18.2. Product Portfolio

            18.1.18.3. Profitability by Market Segments

            18.1.18.4. Sales Footprint

            18.1.18.5. Strategy Overview

                18.1.18.5.1. Marketing Strategy

        18.1.19. Psyadon Pharmaceuticals, Inc.

            18.1.19.1. Overview

            18.1.19.2. Product Portfolio

            18.1.19.3. Profitability by Market Segments

            18.1.19.4. Sales Footprint

            18.1.19.5. Strategy Overview

                18.1.19.5.1. Marketing Strategy

        18.1.20. Cipla Inc.

            18.1.20.1. Overview

            18.1.20.2. Product Portfolio

            18.1.20.3. Profitability by Market Segments

            18.1.20.4. Sales Footprint

            18.1.20.5. Strategy Overview

                18.1.20.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Neurodegenerative Disease Market Value (US$ Mn) Forecast by Region, 2017-2032

Table 2: Global Neurodegenerative Disease Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032

Table 3: Global Neurodegenerative Disease Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 4: Global Neurodegenerative Disease Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032

Table 5: Global Neurodegenerative Disease Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 6: North America Neurodegenerative Disease Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 7: North America Neurodegenerative Disease Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032

Table 8: North America Neurodegenerative Disease Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 9: North America Neurodegenerative Disease Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032

Table 10: North America Neurodegenerative Disease Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 11: Latin America Neurodegenerative Disease Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 12: Latin America Neurodegenerative Disease Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032

Table 13: Latin America Neurodegenerative Disease Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 14: Latin America Neurodegenerative Disease Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032

Table 15: Latin America Neurodegenerative Disease Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 16: Europe Neurodegenerative Disease Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 17: Europe Neurodegenerative Disease Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032

Table 18: Europe Neurodegenerative Disease Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 19: Europe Neurodegenerative Disease Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032

Table 20: Europe Neurodegenerative Disease Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 21: East Asia Neurodegenerative Disease Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 22: East Asia Neurodegenerative Disease Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032

Table 23: East Asia Neurodegenerative Disease Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 24: East Asia Neurodegenerative Disease Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032

Table 25: East Asia Neurodegenerative Disease Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 26: South Asia & Pacific Neurodegenerative Disease Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 27: South Asia & Pacific Neurodegenerative Disease Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032

Table 28: South Asia & Pacific Neurodegenerative Disease Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 29: South Asia & Pacific Neurodegenerative Disease Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032

Table 30: South Asia & Pacific Neurodegenerative Disease Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 31: MEA Neurodegenerative Disease Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 32: MEA Neurodegenerative Disease Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032

Table 33: MEA Neurodegenerative Disease Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 34: MEA Neurodegenerative Disease Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032

Table 35: MEA Neurodegenerative Disease Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Neurodegenerative Disease Market Value (US$ Mn) by Disease Indication, 2022-2032

Figure 2: Global Neurodegenerative Disease Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 3: Global Neurodegenerative Disease Market Value (US$ Mn) by Route of Administration, 2022-2032

Figure 4: Global Neurodegenerative Disease Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 5: Global Neurodegenerative Disease Market Value (US$ Mn) by Region, 2022-2032

Figure 6: Global Neurodegenerative Disease Market Value (US$ Mn) Analysis by Region, 2017-2032

Figure 7: Global Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 8: Global Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 9: Global Neurodegenerative Disease Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032

Figure 10: Global Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032

Figure 11: Global Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032

Figure 12: Global Neurodegenerative Disease Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 13: Global Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 14: Global Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 15: Global Neurodegenerative Disease Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032

Figure 16: Global Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032

Figure 17: Global Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032

Figure 18: Global Neurodegenerative Disease Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 19: Global Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 20: Global Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 21: Global Neurodegenerative Disease Market Attractiveness by Disease Indication, 2022-2032

Figure 22: Global Neurodegenerative Disease Market Attractiveness by Drug Class, 2022-2032

Figure 23: Global Neurodegenerative Disease Market Attractiveness by Route of Administration, 2022-2032

Figure 24: Global Neurodegenerative Disease Market Attractiveness by Distribution Channel, 2022-2032

Figure 25: Global Neurodegenerative Disease Market Attractiveness by Region, 2022-2032

Figure 26: North America Neurodegenerative Disease Market Value (US$ Mn) by Disease Indication, 2022-2032

Figure 27: North America Neurodegenerative Disease Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 28: North America Neurodegenerative Disease Market Value (US$ Mn) by Route of Administration, 2022-2032

Figure 29: North America Neurodegenerative Disease Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 30: North America Neurodegenerative Disease Market Value (US$ Mn) by Country, 2022-2032

Figure 31: North America Neurodegenerative Disease Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 32: North America Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 33: North America Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 34: North America Neurodegenerative Disease Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032

Figure 35: North America Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032

Figure 36: North America Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032

Figure 37: North America Neurodegenerative Disease Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 38: North America Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 39: North America Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 40: North America Neurodegenerative Disease Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032

Figure 41: North America Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032

Figure 42: North America Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032

Figure 43: North America Neurodegenerative Disease Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 44: North America Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 45: North America Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 46: North America Neurodegenerative Disease Market Attractiveness by Disease Indication, 2022-2032

Figure 47: North America Neurodegenerative Disease Market Attractiveness by Drug Class, 2022-2032

Figure 48: North America Neurodegenerative Disease Market Attractiveness by Route of Administration, 2022-2032

Figure 49: North America Neurodegenerative Disease Market Attractiveness by Distribution Channel, 2022-2032

Figure 50: North America Neurodegenerative Disease Market Attractiveness by Country, 2022-2032

Figure 51: Latin America Neurodegenerative Disease Market Value (US$ Mn) by Disease Indication, 2022-2032

Figure 52: Latin America Neurodegenerative Disease Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 53: Latin America Neurodegenerative Disease Market Value (US$ Mn) by Route of Administration, 2022-2032

Figure 54: Latin America Neurodegenerative Disease Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 55: Latin America Neurodegenerative Disease Market Value (US$ Mn) by Country, 2022-2032

Figure 56: Latin America Neurodegenerative Disease Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 57: Latin America Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 58: Latin America Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 59: Latin America Neurodegenerative Disease Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032

Figure 60: Latin America Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032

Figure 61: Latin America Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032

Figure 62: Latin America Neurodegenerative Disease Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 63: Latin America Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 64: Latin America Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 65: Latin America Neurodegenerative Disease Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032

Figure 66: Latin America Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032

Figure 67: Latin America Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032

Figure 68: Latin America Neurodegenerative Disease Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 69: Latin America Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 70: Latin America Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 71: Latin America Neurodegenerative Disease Market Attractiveness by Disease Indication, 2022-2032

Figure 72: Latin America Neurodegenerative Disease Market Attractiveness by Drug Class, 2022-2032

Figure 73: Latin America Neurodegenerative Disease Market Attractiveness by Route of Administration, 2022-2032

Figure 74: Latin America Neurodegenerative Disease Market Attractiveness by Distribution Channel, 2022-2032

Figure 75: Latin America Neurodegenerative Disease Market Attractiveness by Country, 2022-2032

Figure 76: Europe Neurodegenerative Disease Market Value (US$ Mn) by Disease Indication, 2022-2032

Figure 77: Europe Neurodegenerative Disease Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 78: Europe Neurodegenerative Disease Market Value (US$ Mn) by Route of Administration, 2022-2032

Figure 79: Europe Neurodegenerative Disease Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 80: Europe Neurodegenerative Disease Market Value (US$ Mn) by Country, 2022-2032

Figure 81: Europe Neurodegenerative Disease Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 82: Europe Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 83: Europe Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 84: Europe Neurodegenerative Disease Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032

Figure 85: Europe Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032

Figure 86: Europe Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032

Figure 87: Europe Neurodegenerative Disease Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 88: Europe Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 89: Europe Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 90: Europe Neurodegenerative Disease Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032

Figure 91: Europe Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032

Figure 92: Europe Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032

Figure 93: Europe Neurodegenerative Disease Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 94: Europe Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 95: Europe Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 96: Europe Neurodegenerative Disease Market Attractiveness by Disease Indication, 2022-2032

Figure 97: Europe Neurodegenerative Disease Market Attractiveness by Drug Class, 2022-2032

Figure 98: Europe Neurodegenerative Disease Market Attractiveness by Route of Administration, 2022-2032

Figure 99: Europe Neurodegenerative Disease Market Attractiveness by Distribution Channel, 2022-2032

Figure 100: Europe Neurodegenerative Disease Market Attractiveness by Country, 2022-2032

Figure 101: East Asia Neurodegenerative Disease Market Value (US$ Mn) by Disease Indication, 2022-2032

Figure 102: East Asia Neurodegenerative Disease Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 103: East Asia Neurodegenerative Disease Market Value (US$ Mn) by Route of Administration, 2022-2032

Figure 104: East Asia Neurodegenerative Disease Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 105: East Asia Neurodegenerative Disease Market Value (US$ Mn) by Country, 2022-2032

Figure 106: East Asia Neurodegenerative Disease Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 107: East Asia Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 108: East Asia Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 109: East Asia Neurodegenerative Disease Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032

Figure 110: East Asia Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032

Figure 111: East Asia Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032

Figure 112: East Asia Neurodegenerative Disease Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 113: East Asia Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 114: East Asia Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 115: East Asia Neurodegenerative Disease Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032

Figure 116: East Asia Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032

Figure 117: East Asia Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032

Figure 118: East Asia Neurodegenerative Disease Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 119: East Asia Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 120: East Asia Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 121: East Asia Neurodegenerative Disease Market Attractiveness by Disease Indication, 2022-2032

Figure 122: East Asia Neurodegenerative Disease Market Attractiveness by Drug Class, 2022-2032

Figure 123: East Asia Neurodegenerative Disease Market Attractiveness by Route of Administration, 2022-2032

Figure 124: East Asia Neurodegenerative Disease Market Attractiveness by Distribution Channel, 2022-2032

Figure 125: East Asia Neurodegenerative Disease Market Attractiveness by Country, 2022-2032

Figure 126: South Asia & Pacific Neurodegenerative Disease Market Value (US$ Mn) by Disease Indication, 2022-2032

Figure 127: South Asia & Pacific Neurodegenerative Disease Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 128: South Asia & Pacific Neurodegenerative Disease Market Value (US$ Mn) by Route of Administration, 2022-2032

Figure 129: South Asia & Pacific Neurodegenerative Disease Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 130: South Asia & Pacific Neurodegenerative Disease Market Value (US$ Mn) by Country, 2022-2032

Figure 131: South Asia & Pacific Neurodegenerative Disease Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 132: South Asia & Pacific Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 133: South Asia & Pacific Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 134: South Asia & Pacific Neurodegenerative Disease Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032

Figure 135: South Asia & Pacific Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032

Figure 136: South Asia & Pacific Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032

Figure 137: South Asia & Pacific Neurodegenerative Disease Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 138: South Asia & Pacific Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 139: South Asia & Pacific Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 140: South Asia & Pacific Neurodegenerative Disease Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032

Figure 141: South Asia & Pacific Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032

Figure 142: South Asia & Pacific Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032

Figure 143: South Asia & Pacific Neurodegenerative Disease Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 144: South Asia & Pacific Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 145: South Asia & Pacific Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 146: South Asia & Pacific Neurodegenerative Disease Market Attractiveness by Disease Indication, 2022-2032

Figure 147: South Asia & Pacific Neurodegenerative Disease Market Attractiveness by Drug Class, 2022-2032

Figure 148: South Asia & Pacific Neurodegenerative Disease Market Attractiveness by Route of Administration, 2022-2032

Figure 149: South Asia & Pacific Neurodegenerative Disease Market Attractiveness by Distribution Channel, 2022-2032

Figure 150: South Asia & Pacific Neurodegenerative Disease Market Attractiveness by Country, 2022-2032

Figure 151: MEA Neurodegenerative Disease Market Value (US$ Mn) by Disease Indication, 2022-2032

Figure 152: MEA Neurodegenerative Disease Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 153: MEA Neurodegenerative Disease Market Value (US$ Mn) by Route of Administration, 2022-2032

Figure 154: MEA Neurodegenerative Disease Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 155: MEA Neurodegenerative Disease Market Value (US$ Mn) by Country, 2022-2032

Figure 156: MEA Neurodegenerative Disease Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 157: MEA Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 158: MEA Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 159: MEA Neurodegenerative Disease Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032

Figure 160: MEA Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032

Figure 161: MEA Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032

Figure 162: MEA Neurodegenerative Disease Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 163: MEA Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 164: MEA Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 165: MEA Neurodegenerative Disease Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032

Figure 166: MEA Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032

Figure 167: MEA Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032

Figure 168: MEA Neurodegenerative Disease Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 169: MEA Neurodegenerative Disease Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 170: MEA Neurodegenerative Disease Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 171: MEA Neurodegenerative Disease Market Attractiveness by Disease Indication, 2022-2032

Figure 172: MEA Neurodegenerative Disease Market Attractiveness by Drug Class, 2022-2032

Figure 173: MEA Neurodegenerative Disease Market Attractiveness by Route of Administration, 2022-2032

Figure 174: MEA Neurodegenerative Disease Market Attractiveness by Distribution Channel, 2022-2032

Figure 175: MEA Neurodegenerative Disease Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

MRI-Safe Neurostimulation Systems Market

Published : September 2017

Healthcare

Neuroendocrine Carcinoma Treatment Market

Published : March 2022

Healthcare

Neurointerventional Devices Market

Published : August 2020

Healthcare

Neurostimulation Market

Published : January 1970

Google translate

Neurodegenerative Disease Market